Oruka Therapeutics has reported positive interim data from the ongoing EVERLAST-A Phase IIa trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.
The randomised, double-blind, placebo-controlled trial of the half-life extended IL-23p19 monoclonal antibody is being conducted at 26 sites across Canada and the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
A total of 84 patients were randomised into a 3:1 ratio to receive either 600mg of ORKA-001 or a matching placebo at weeks zero and four.
Baseline patient characteristics matched recent studies in the same indication.
At week 16, 40 of 63 participants (63.5%) who received ORKA-001 achieved psoriasis area and severity index 100 (PASI 100), the trial’s primary endpoint, corresponding to complete skin clearance.
The same result was observed for investigator’s global assessment 0 (IGA 0).
Secondary endpoints included PASI 90 achieved by 83% of participants and IGA 0/1 by 84% of ORKA-001 recipients. Among 21 placebo recipients, one achieved these endpoints. All response rates used non-responder imputation for analysis.
Safety findings indicated ORKA-001 was well tolerated, with no serious treatment-emergent adverse events and a TEAE rate similar to placebo.
Upper respiratory tract infection was reported in 19% of the ORKA-001 group and 14% in placebo. No injection site reactions were observed.
Pharmacokinetic and pharmacodynamic data from previous trials continue to support the potential for annual dosing, with sustained drug levels and IL-23 pathway inhibition for one year post-dose.
The company aims to announce longer-term EVERLAST-A data in late 2026 and will continue advancing the parallel Phase IIb EVERLAST-B trial, with results expected in 2027.
Oruka Therapeutics chief medical officer Joana Goncalves said: “These data reached the top end of what we could have expected from ORKA-001 across efficacy, tolerability, and potential for long-lasting response.
“We’re thrilled with the profile that is emerging for this programme and are excited to see how the data matures with longer-term follow-up. I want to thank the Oruka team, the EVERLAST-A investigators, and the trial participants for getting this study off to a tremendous start.”
